Core Insights - Shanghai Kehua Bio-engineering Co., Ltd. (KHB) is showcasing its Polaris V150 Automatic Chemiluminescence Immunoassay Analyzer at MEDICA 2025, highlighting its commitment to innovation in automated diagnostics [1][8] Product Features - The Polaris V150 is designed for small and medium-sized laboratories, as well as emergency testing in large hospitals, featuring a compact footprint of only 0.36 m² while delivering 150 tests per hour [2][3] - It supports continuous loading of samples and reagents, prioritizing urgent samples through its STAT function, and includes automated dilution and various detection features to enhance workflow reliability [3] - The analyzer utilizes a high-performance ALP–AMPPD chemiluminescence system, achieving high accuracy with a coefficient of variation (CV) of less than 3% across assays [4] - It offers a comprehensive test menu with over 60 assays across 10 major disease panels, addressing a wide range of diagnostic needs [5] User Experience and Maintenance - The Polaris V150 features an intelligent system design for real-time monitoring of reagent status, a user-friendly interface, and built-in touchscreen for efficient navigation [6] - It includes 24-hour onboard refrigeration for optimal reagent stability and smart maintenance features to reduce downtime [7] Market Reception - The product has garnered significant interest at MEDICA 2025, indicating strong demand for compact, high-quality chemiluminescence systems [9]

证券日报网讯 科华生物（002022）11月17日在互动平台回答投资者提问时表示，根据公司于2025年10 月30日披露的《2025年第三季度报告》，截至2025年9月30日，公司股东总数为48，108户。 ...

证券日报网讯科华生物（002022）11月6日在互动平台回答投资者提问时表示，关于公司与西安经济技 术开发区管委会签署的投资合作协议涉及的各项后续事宜，公司将严格按照相关法律法规和《公司章 程》的有关规定，及时履行相应的审批程序和信息披露义务，请以公司后续披露的公告为准。 ...

Core Insights - Kewah Bio's stock price increased by 2.03% on October 31, reaching 6.54 CNY per share, with a market capitalization of 3.364 billion CNY [1] - The company reported a revenue of 1.191 billion CNY for the first nine months of 2025, a year-on-year decrease of 11.77%, and a net profit of -233 million CNY, down 90.38% year-on-year [2] Financial Performance - Year-to-date stock price change is an increase of 3.65%, with a recent decline of 0.61% over the last five trading days [1] - The company has cumulatively distributed 1.694 billion CNY in dividends since its A-share listing, with 309 million CNY distributed in the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 13.91% to 48,100, while the average number of circulating shares per person decreased by 12.21% to 10,689 shares [2] - The sixth largest circulating shareholder is the Medical Device ETF (159883), which holds 3.1732 million shares as a new entrant [3]

Core Viewpoint - Kehua Bio is a leading company in the in vitro diagnostics sector in China, with a comprehensive product range and a focus on research, production, and sales of various diagnostic reagents and instruments [1] Group 1: Business Performance - In Q3 2025, Kehua Bio reported revenue of 1.191 billion yuan, ranking 7th in the industry out of 39 companies [2] - The company's net profit for the same period was -254 million yuan, placing it last in the industry [2] - The main business composition includes agency products at 395 million yuan (49.76%), self-produced products at 371 million yuan (46.73%), and other revenues at 27.86 million yuan (3.51%) [2] Group 2: Financial Ratios - As of Q3 2025, Kehua Bio's debt-to-asset ratio was 27.53%, an increase from 20.10% in the previous year, exceeding the industry average of 18.29% [3] - The gross profit margin for Q3 2025 was 35.81%, down from 40.04% year-on-year, and below the industry average of 56.20% [3] Group 3: Executive Compensation - The chairman and president, Li Ming, received a salary of 2.0822 million yuan in 2024, an increase of 126,600 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 13.91% to 48,100 [5] - The average number of circulating A-shares held per shareholder decreased by 12.21% to 10,700 [5] - The sixth largest circulating shareholder is a medical device ETF, which holds 3.1732 million shares as a new shareholder [5]

Core Viewpoint - The company plans to utilize up to 500 million RMB of idle funds for cash management to enhance fund efficiency and increase returns [1][2] Group 1: Cash Management Proposal - The company and its subsidiaries will use a total of no more than 500 million RMB for cash management, investing in low-risk, high-liquidity financial products [1][2] - The primary goal is to activate idle funds without affecting daily operational cash flow and normal business activities [1][2] Group 2: Investment Guidelines - The investment will be limited to financial products issued by banks, fund companies, securities companies, and insurance companies, with a maximum investment period of 12 months [2] - The company will not invest in securities, unsecured bonds, domestic and foreign stocks, or any high-risk investment products [2] Group 3: Risk Management Measures - The finance department will continuously analyze and monitor the investment products, with the audit department and independent directors having oversight authority [3] - The investment strategy is based on principles of "standard operation, risk control, cautious investment, and value preservation," ensuring that daily operations and fund safety are prioritized [3] Group 4: Meeting and Documentation - The proposal was approved during the 18th meeting of the 10th Board of Directors, and relevant documents include the meeting resolution [4]

Core Points - The company Kewah Bio (002022) announced the election of Mr. Yi Chao as the employee representative director of the 10th Board of Directors during the employee representative meeting held on October 29, 2025 [1] Summary by Category - **Company Announcement** - Kewah Bio held an employee representative meeting on October 29, 2025, where Mr. Yi Chao was elected as the employee representative director [1]

关于产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，上海科华生物工程股份有限公司（以下简称"公司"）控股子公司西 安天隆科技有限公司收到国家药品监督管理局颁发的医疗器械注册证。具体情况 如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期 | 适用范围/预期用途 | | --- | --- | --- | --- | --- | | | 全自动核酸 检测分析仪 | 国械注准 20253222101 | 2025年10月27日 | 本产品基于实时荧光PCR检测原理， 与配套的检测试剂共同使用，在临床 | | 1 | | | 至 | 上用于对来源于人体样本中的靶核 | | | | | 2030年10月26日 | 酸（DNA/RNA）进行定性检测，包括 | | | | | | 病原体和人类基因检测项目。 | 以上新产品医疗器械注册证的取得，丰富了公司产品线，将对公司业务发展 具有正面影响。公司目前尚无法预测上述产品对公司未来营业收入的影响，敬请 投资者给予关注并注意投资风险。 | 证券代码：002022 | 证券简称： ...

证券代码：002022 证券简称：科华生物 公告编号：2025-068 债券代码：128124 债券简称：科华转债 | 证券代码:002022 | | --- | | 债券代码:128124 | 上海科华生物工程股份有限公司 关于董事辞职暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事辞职情况 上海科华生物工程股份有限公司（以下简称"公司"）董事会于近日收到公 司非独立董事金红英女士提交的书面辞职报告。因公司治理结构调整，金红英女 士申请辞去第十届董事会非独立董事及战略委员会委员职务，辞去上述职务后， 金红英女士仍继续担任公司副总裁、董事会秘书职务。金红英女士的辞职不会导 致公司董事会成员低于法定最低人数，不会影响公司董事会及战略委员会的正常 运作。根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海科 华生物工程股份有限公司章程》（以下简称"《公司章程》"）等相关规定，辞 职报告自送达董事会时生效。 金红英女士担任董事的原定任期至第十届董事会届满之日（2027年3月19日） 止。截至本公告披露日，金红英女士未持有公 ...

证券代码：002022 证券简称：科华生物 公告编号：2025-071 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 关于公司及子公司使用自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、投资种类：安全性高、流动性好、风险低、产品投资期限最长不超过12 个月的理财产品。 2、投资金额：不超过人民币50,000万元，资金可在上述额度内循环使用， 任一时点现金管理的余额（含前述投资的收益进行再投资的相关金额）不超过人 民币50,000万元。 3、特别风险提示：公司及子公司拟投资理财产品属于低风险投资品种，但 金融市场受宏观经济的影响较大，不排除该项投资受到市场波动的影响；公司将 根据经济形势以及金融市场的变化适时适量介入，因此短期投资的实际收益不可 预期，敬请投资者注意投资风险。 上海科华生物工程股份有限公司（以下简称"公司"）于2025年10月29日召 开第十届董事会第十八次会议，审议通过了《关于公司及子公司使用自有资金进 行现金管理的议案》，同意公司及全资、控股子公司（均为合并报表范围内 ...